Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity

28 Jul 2010

Abstract excerpt

BACKGROUND: HER2 gene copy status, and concomitant administration of trastuzumab (Herceptin), remains one of the best examples of targeted cancer therapy based on understanding the genomic etiology of disease. However, newly diagnosed breast cancer cases with equivocal HER2 results present a challenge for the oncologist who must make treatment decisions despite the patient's unresolved HER2 status. In some cases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene expression and cancer classification
Share to Genomic variations and chromosomal abnormalities
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20667129
DOI: 10.1186/1471-2407-10-396

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexityPMID 20667129Read ↗

Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort studySemantic proximity Read ↗

Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancerSemantic proximity Read ↗

Genomic Copy Number Analysis of HER2-Equivocal Breast Cancers.Semantic proximity Read ↗

Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.Semantic proximity Read ↗

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trialsSemantic proximity Read ↗

The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity.Semantic proximity Read ↗

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Semantic proximity Read ↗

Association of <i>HER-2</i> Copy Number and <i>HER-2/CEP-17</i> Ratio with Neoadjuvant Taxane-Containing Chemotherapy Sensitivity in Locally Advanced Breast CancerSemantic proximity Read ↗

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 TestingSemantic proximity Read ↗

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.Semantic proximity Read ↗

<i>HER2</i> genetic heterogeneity in breast carcinomaSemantic proximity Read ↗

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily PracticeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.